Grünenthal Italia

Grünenthal Italia company information, Employees & Contact Information

Da oltre 45 anni nel Dolore. Grünenthal ha sviluppato in Italia la gestione del dolore e continua ad evolverla insieme a medici e pazienti perseguendo la vision di 'Un mondo Libero dal Dolore' In Italia vanta anche la presenza del sito produttivo di Origgio, l’impianto produttivo di 50.000 mq2 ha attualmente una capacità produttiva in grado di erogare fino a 2 miliardi di singole unità all'anno e di esportare il 98% della produzione in Europa, Asia e Sud America. Entrambe le realtà del gruppo sono certificate da Bureau Veritas per la Parità di Genere e quali Great Place to Work. Eccellenze certificate, con un'occupazione qualificata, che offrono un portfolio di soluzioni e servizi a medici e pazienti, nonché servizi di produzione, assemblaggio e confezionamento anche conto terzi. Per saperne di segui Grünenthal Italia e visita il sito grunenthal.it. Nell’ambito del nostro impegno per la trasparenza e i principi delineati nella nostra digital ethics charter (https:/www.grunenthal.com/-/media/projects/corporatewebsite/com/pdf/position-papers/2021/digital_ethics_charter_2021.pdf), Grünenthal desidera informarvi che le tecnologie di intelligenza artificiale generativa sono occasionalmente utilizzate per migliorare i contenuti di questo canale. In tal caso, prima della pubblicazione, ogni contenuto viene revisionato e modificato dal team Grünenthal al fine di garantirne l'accuratezza.

Company Details

Employees
218
Founded
-
Address
Via Carlo Bo, 11, Milano,lombardia 20143,italy
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Manager jobs.
HQ
Milano, Lombardia
Looking for a particular Grünenthal Italia employee's phone or email?

Grünenthal Italia Questions

News

Grünenthal goes for Cialis in latest targeted acquisition - The Pharma Letter

Grünenthal goes for Cialis in latest targeted acquisition The Pharma Letter

Grünenthal delivers exceptional financial results in 2024 - The Pharma Letter

Grünenthal delivers exceptional financial results in 2024 The Pharma Letter

Grünenthal acquires Valinor Pharma - Pharmaceutical Technology

Grünenthal acquires Valinor Pharma Pharmaceutical Technology

Grünenthal designates $87M to update plants in Ecuador and Chile - Fierce Pharma

Grünenthal designates $87M to update plants in Ecuador and Chile Fierce Pharma

Opioids: Old high, new low - DW

Opioids: Old high, new low DW

Dr. Frances Kelsey vs. Chemie Grünenthal - Global Biodefense

Dr. Frances Kelsey vs. Chemie Grünenthal Global Biodefense

Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy - Labiotech.eu

Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy Labiotech.eu

AZ sells rights to statin med Crestor to Grünenthal - PharmaTimes

AZ sells rights to statin med Crestor to Grünenthal PharmaTimes

Mundipharma signs Chinese licensing and distribution agreement with Grünenthal - Pharmafile

Mundipharma signs Chinese licensing and distribution agreement with Grünenthal Pharmafile

Grünenthal identifies new Nav1.8 blockers for pain - BioWorld MedTech

Grünenthal identifies new Nav1.8 blockers for pain BioWorld MedTech

Grünenthal buys Thar to expand late-phase pain pipeline - Fierce Biotech

Grünenthal buys Thar to expand late-phase pain pipeline Fierce Biotech

Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M - Genetic Engineering and Biotechnology News

Grünenthal Acquires Partial Rights to Nexium, Vimovo from AstraZeneca for Up-to-$922M Genetic Engineering and Biotechnology News

Kyowa Kirin offloads mature drugs to Grünenthal amid 'challenging business environment' - Fierce Pharma

Kyowa Kirin offloads mature drugs to Grünenthal amid 'challenging business environment' Fierce Pharma

Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management - Fierce Pharma

Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management Fierce Pharma

Jan Adams to replace Janneke van der Kamp as Grünenthal CCO - The Pharma Letter

Jan Adams to replace Janneke van der Kamp as Grünenthal CCO The Pharma Letter

Grünenthal continues US growth push with $250M acquisition of Valinor Pharma - Fierce Pharma

Grünenthal continues US growth push with $250M acquisition of Valinor Pharma Fierce Pharma

Grünenthal announces pricing of 500 million-euro bond - The Pharma Letter

Grünenthal announces pricing of 500 million-euro bond The Pharma Letter

In $500M deal, Bayer offloads testosterone deficiency drug Nebido to Grünenthal - Fierce Pharma

In $500M deal, Bayer offloads testosterone deficiency drug Nebido to Grünenthal Fierce Pharma

AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covis - Fierce Pharma

AstraZeneca resumes asset sale in $270M COPD deal with familiar buyer Covis Fierce Pharma

AstraZeneca hands European Crestor rights to old customer Grünenthal for $350M - Fierce Pharma

AstraZeneca hands European Crestor rights to old customer Grünenthal for $350M Fierce Pharma

AZ jilts gout med Zurampic with $230M rights sale to Grunenthal - Fierce Pharma

AZ jilts gout med Zurampic with $230M rights sale to Grunenthal Fierce Pharma

Grünenthal and Freshfields win injunction against Teva testosterone drug - JUVE Patent

Grünenthal and Freshfields win injunction against Teva testosterone drug JUVE Patent

Grunenthal insists crush-proof tablet works after Endo pulls Opana sNDA - Fierce Pharma

Grunenthal insists crush-proof tablet works after Endo pulls Opana sNDA Fierce Pharma

New Grunenthal CEO Forges Ahead with Treatment for Complex Regional Pain Syndrome - BioSpace

New Grunenthal CEO Forges Ahead with Treatment for Complex Regional Pain Syndrome BioSpace

Scientists quit back pain campaign over links to opioid giant Grünenthal - The Times

Scientists quit back pain campaign over links to opioid giant Grünenthal The Times

AstraZeneca Divests Two Drugs to Grünenthal in $90 Million Deal - BioSpace

AstraZeneca Divests Two Drugs to Grünenthal in $90 Million Deal BioSpace

Nazis, lies and spying private detectives: how thalidomide’s maker avoided justice - The Conversation

Nazis, lies and spying private detectives: how thalidomide’s maker avoided justice The Conversation

An Opioid Popularized by a Nazi Doctor Is Ravaging Africa - VICE

An Opioid Popularized by a Nazi Doctor Is Ravaging Africa VICE

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia - Via Ritzau

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia Via Ritzau

AZ’s Gabriel Baertschi joins Grünenthal as CEO - PMLiVE

AZ’s Gabriel Baertschi joins Grünenthal as CEO PMLiVE

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik® - Via Ritzau

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik® Via Ritzau

Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors - Via Ritzau

Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors Via Ritzau

Maren Thurow starts as new Head Global Communications at Grünenthal | Grünenthal Group - Via Ritzau

Maren Thurow starts as new Head Global Communications at Grünenthal | Grünenthal Group Via Ritzau

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer - Via Ritzau

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer Via Ritzau

Grunenthal to market MSD’s pain drug - PMLiVE

Grunenthal to market MSD’s pain drug PMLiVE

Grünenthal Group: Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer - NTB Kommunikasjon

Grünenthal Group: Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer NTB Kommunikasjon

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients - Via Ritzau

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients Via Ritzau

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million - Via Ritzau

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million Via Ritzau

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer | news aktuell GmbH - NTB Kommunikasjon

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer | news aktuell GmbH NTB Kommunikasjon

Nazis who got rich from deformed baby drug - Morning Star | The People’s Daily

Nazis who got rich from deformed baby drug Morning Star | The People’s Daily

Stuart Cosgrove: Cause for applause for women who stood up against thalidomide - TheNational.scot

Stuart Cosgrove: Cause for applause for women who stood up against thalidomide TheNational.scot

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients - STT Info

Grünenthal announces significant investments in its Latin America production sites, further securing reliable medicine supply for patients STT Info

German Grünenthal Group acquires Adhesys Medical for its surgical sealant technology - Tech.eu

German Grünenthal Group acquires Adhesys Medical for its surgical sealant technology Tech.eu

Grünenthal closes deal with AstraZeneca - Irish Medical Times

Grünenthal closes deal with AstraZeneca Irish Medical Times

1968 In Photos: The High Court Agrees Meagre Compensation For Thalidomide Victims - Flashbak

1968 In Photos: The High Court Agrees Meagre Compensation For Thalidomide Victims Flashbak

I dipendenti Grünental donano parte del premio alla "Casa di Giordy", in memoria di Giordana Di - Fedaiisf

I dipendenti Grünental donano parte del premio alla "Casa di Giordy", in memoria di Giordana Di Fedaiisf

'˜You cannot put a price on not having legs' - Belfast News Letter

'˜You cannot put a price on not having legs' Belfast News Letter

Top Grünenthal Italia Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant